



Esperion Therapeutics, Inc.
Investor Relations Department
3891 Ranchero Drive
Suite 150
Ann Arbor, MI 48108
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: ESPR

| | |
|---------------|--|
| Last Trade: | 49.31 |
| Trade Time: | 4:00 PM ET Sep 22, 2017 |
| Change: | -0.06 ▼ (-0.122%) |
| Day Range | 48.00 - 50.19 |
| 52-Week Range | 9.40 - 57.38 |
| Volume | 412,757 |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, non-statin, once-daily, oral therapies to lower elevated low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is "patient-friendly, physician-frie... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Aug 11, 2017

[Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

Aug 9, 2017

[Esperion Prices Public Offering of Common Stock](#)

Aug 8, 2017

[Esperion Announces Proposed Public Offering of Common Stock](#)

Aug 8, 2017

[Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2017 Financial Results](#)

Aug 8, 2017

[Esperion Announces Positive Top-Line Results From Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin](#)

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

Feb 22, 2017

[Annual Report \(10-K\)](#)

Mar 6, 2017

[Proxy Statement \(DEF 14A\)](#)

Aug 8, 2017

[Quarterly Report \(10-Q\)](#)

May 4, 2017

[Quarterly Report \(10-Q\)](#)

Nov 3, 2016

[Quarterly Report \(10-Q\)](#)